These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29714832)

  • 1. Successful Therapy with Nivolumab in Metastatic Renal Cell Carcinoma After Multiple Prior Treatments.
    Finelli NC; Baig SA; Masters GA
    Del Med J; 2017 Jan; 89(1):14-17. PubMed ID: 29714832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab in the treatment of advanced renal cell carcinoma.
    Arasaratnam M; Gurney H
    Future Oncol; 2018 Jul; 14(17):1679-1689. PubMed ID: 29460635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.
    Thornton Snider J; Batt K; Wu Y; Tebeka MG; Seabury S
    Am J Manag Care; 2017 Oct; 23(10):e340-e346. PubMed ID: 29087638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features.
    Geynisman DM
    Eur Urol; 2015 Nov; 68(5):912-4. PubMed ID: 26194044
    [No Abstract]   [Full Text] [Related]  

  • 5. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
    Ornstein MC; Rini BI
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.
    Noguchi G; Tsutsumi S; Yasui M; Ohtake S; Umemoto S; Nakaigawa N; Yao M; Kishida T
    BMC Urol; 2018 Apr; 18(1):26. PubMed ID: 29669553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
    Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
    Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
    Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metastatic renal cell carcinoma, back to the future].
    Martins F; Berthold D
    Rev Med Suisse; 2016 May; 12(519):994-8. PubMed ID: 27424427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
    Zarrabi K; Wu S
    Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program.
    Bracarda S; Galli L; Maruzzo M; Lo Re G; Buti S; Favaretto A; Di Costanzo F; Sacco C; Merlano M; Mucciarini C; Zafarana E; Romito S; Maestri A; Giorgio CG; Ionta MT; Turci D; De Giorgi U; Procopio G; Cortesi E; Giannarelli D; Porta C
    Future Oncol; 2018 Jun; 14(14):1347-1354. PubMed ID: 29774766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Initial Clinical Experience of Nivolumab for Metastatic Renal Cell Carcinoma].
    Fukunaga A; Yamasaki T; Okuno T; Imai K; Ikeuchi R; Hishiki K; Goto T; Sawada A; Negoro H; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
    Hinyokika Kiyo; 2018 Oct; 64(10):383-389. PubMed ID: 30543735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pushing the limits of immune-related response: a case of "extreme pseudoprogression".
    Wong AS; Thian YL; Kapur J; Leong CN; Kee P; Lee CT; Lee MB
    Cancer Immunol Immunother; 2018 Jul; 67(7):1105-1111. PubMed ID: 29728723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).
    Atkins MB; Philips GK
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):243-54. PubMed ID: 27539246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence.
    Adrianzen Herrera DA; Fleisig SB; Gartrell BA
    Invest New Drugs; 2017 Oct; 35(5):665-668. PubMed ID: 28466375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney metastases.
    Dresler CM
    Chest Surg Clin N Am; 1998 Feb; 8(1):127-9. PubMed ID: 9515177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
    Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
    Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
    Xie XD; Piao Y; Liu ZZ
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted Therapy for Renal Cell Carcinoma.
    Joshi R; Rawal S
    JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.